Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins

被引:152
作者
Kim, TW
Hung, CF
Ling, M
Juang, J
He, LM
Hardwick, JM
Kumar, S
Wu, TC
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[3] Johns Hopkins Med Inst, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
[4] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21205 USA
[5] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[6] J Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA, Australia
[7] Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA
关键词
D O I
10.1172/JCI200317293
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Intradermal vaccination by gene gun efficiently delivers DNA vaccines into DCs of the skin, resulting in the activation and priming of antigen-specific T cells in vivo. DCs, however, have a limited life span, hindering their long-term ability to prime antigen-specific T cells. We reason that a strategy that prolongs the survival of DNA-transduced DCs will enhance priming of antigen-specific T cells and DNA vaccine potency. Here we show that codelivery of DNA encoding inhibitors of apoptosis (BCL-xL, BCL-2, XIAP, dominant negative caspase-9, or dominant negative caspase-8) with DNA encoding model antigens prolongs the survival of transduced DCs. More importantly, vaccinated mice exhibited significant enhancement in antigen-specific CD8(+) T cell immune responses, resulting in a potent antitumor effect against antigen-expressing tumors. Among these antiapoptotic factors, BCL-xL demonstrated the greatest enhancement in antigen-specific immune responses and antitumor effects. Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency.
引用
收藏
页码:109 / 117
页数:9
相关论文
共 38 条
[1]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[2]   Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis [J].
Chattergoon, MA ;
Kim, JJ ;
Yang, JS ;
Robinson, TM ;
Lee, DJ ;
Dentchev, T ;
Wilson, DM ;
Ayyavoo, V ;
Weiner, DB .
NATURE BIOTECHNOLOGY, 2000, 18 (09) :974-979
[3]  
Chen CH, 2000, CANCER RES, V60, P1035
[4]   Bax-independent inhibition of apoptosis by Bcl-x(L) [J].
Cheng, EHY ;
Levine, B ;
Boise, LH ;
Thompson, CB ;
Hardwick, JM .
NATURE, 1996, 379 (6565) :554-556
[5]   Conversion of Bcl-2 to a Bax-like death effector by caspases [J].
Cheng, EHY ;
Kirsch, DG ;
Clem, RJ ;
Ravi, R ;
Kastan, MB ;
Bedi, A ;
Ueno, K ;
Hardwick, JM .
SCIENCE, 1997, 278 (5345) :1966-1968
[6]   Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen [J].
Cheng, WF ;
Hung, CF ;
Chai, CY ;
Hsu, KF ;
He, LM ;
Ling, M ;
Wu, TC .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (05) :669-678
[7]   c-IAP1 is cleaved by caspases to produce a proapoptotic C-terminal fragment [J].
Clem, RJ ;
Sheu, TT ;
Richter, BWM ;
He, WW ;
Thornberry, NA ;
Duckett, CS ;
Hardwick, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) :7602-7608
[8]   Conversion of procaspase-3 to an autoactivating caspase by fusion to the caspase-2 prodomain [J].
Colussi, PA ;
Harvey, NL ;
Shearwin-Whyatt, LM ;
Kumar, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26566-26570
[9]   DNA-based immunization by in vivo transfection of dendritic cells [J].
Condon, C ;
Watkins, SC ;
Celluzzi, CM ;
Thompson, K ;
Falo, LD .
NATURE MEDICINE, 1996, 2 (10) :1122-1128
[10]   X-linked IAP is a direct inhibitor of cell-death proteases [J].
Deveraux, QL ;
Takahashi, R ;
Salvesen, GS ;
Reed, JC .
NATURE, 1997, 388 (6639) :300-304